This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
HanAll Biopharma Co., Ltd.
Drug Names(s): HL143, HL-143, Engineered interferon alpha-2b
Description: HL143 is a single amino acid variant of native IFN-alpha-2a that utilizes Resistein technology to engineer a protease resistant variant that has longer half-life compared to native IFN-alpha.
Additional information available to subscribers only: